Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763637 | 0.87 | MAPT (0.57) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL7763641 | 0.87 | MAPT (0.57) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL8246035 | 0.86 | CTSS (0.56) | SIRT2SIRT1SIRT3SIRT5CTSS | |
| SCHEMBL5301318 | 0.86 | CTSS (0.56) | SIRT2SIRT1SIRT3SIRT5CTSS | |
| SCHEMBL4602404 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL1024713 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL30962415 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL6621271 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL5308048 | 0.82 | SIRT5 (0.59) | SIRT2SIRT1SIRT3SIRT5SYK | |
| SCHEMBL8244805 | 0.82 | SIRT5 (0.59) | SIRT2SIRT1SIRT3SIRT5SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | MAPT 4866/4885SIRT2 1857/4885SIRT1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.